Elutia Inc. (ELUT)
NASDAQ: ELUT · Real-Time Price · USD
1.670
-0.050 (-2.91%)
At close: May 29, 2025, 4:00 PM
1.650
-0.020 (-1.20%)
After-hours: May 29, 2025, 4:00 PM EDT
Elutia Revenue
Elutia had revenue of $6.03M in the quarter ending March 31, 2025, a decrease of -9.92%. This brings the company's revenue in the last twelve months to $23.71M, down -5.33% year-over-year. In the year 2024, Elutia had annual revenue of $24.38M, down -1.50%.
Revenue (ttm)
$23.71M
Revenue Growth
-5.33%
P/S Ratio
2.38
Revenue / Employee
$464,922
Employees
51
Market Cap
68.25M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ELUT News
- 1 day ago - Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method - GlobeNewsWire
- 18 days ago - Elutia Inc. (ELUT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales - GlobeNewsWire
- 4 weeks ago - Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio - GlobeNewsWire
- 4 weeks ago - Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025 - GlobeNewsWire
- 5 weeks ago - Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29 - GlobeNewsWire
- 5 weeks ago - Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice - GlobeNewsWire
- 6 weeks ago - Elutia Confirms No Material Impact from Global Tariffs - GlobeNewsWire